Researchers at Oxford University have discovered a common gene variation which plays a significant role in the occurrence of an adverse side-effect caused by drugs used to reduce cholesterol.

Findings published in the New England Journal of Medicine suggest that a simple genetic test could identify patients at risk of developing 'myopathy' - severe muscle pain and weakness - before being prescribed statins.

Leader of the study, involving 175 patients taking high dose statins, professor Collins and his team of researchers found that a variation in the DNA code of a gene called SLC01B1 was responsible for 60 per cent of the myopathy cases in people taking high dose statin therapy.

According to the results, SLC01B1 regulates the uptake of statins into the liver and the genetic variant appears to influence its function, leading to higher levels of the statins in the blood.

Commenting on the research, professor Collins said: "We believe this is the first time anyone has scanned the complete human genome for the genetic culprit of a drug's side-effect and we're very excited about the results.

"A DNA test based on these findings could guide doctors as to whether a patient at high risk of heart disease will cope with a high dose of a statin, which might be more effective than a standard dose at preventing a heart attack or stroke."

Statin-induced myopathy is very rare, but can result in kidney failure in some cases.

Login and visit the Cholesterol Knowledge Centre

• Cholesterol treatment receives US approval 16/12/08
• Study confirms no interference between cholesterol and lymphoma treatments 09/12/08
• New game could help tackle obesity and diabetes in kids, expert claims 04/12/08
• Some "good cholesterol" not good enough, study suggests 02/12/08
• Study links grapes with reduced cardio risk 29/10/08

• ZOCOR (statin) - 51.11%
  ... cholesterol, LDL-cholesterol, apolipoprotein B and triglycerides in primary hypercholesterolaemia, heterozygous familial hypercholesterolaemia or combined (mixed) hyperlipidaemia when response to diet and other non- pharmacological measures is inadequate. To lower LDL:HDL ratio and total cholesterol ...
  
  
• LIPITOR (statin) - 50.64%
  Adjunct to diet for reduction of elevated total cholesterol, LDL- cholesterol, apolipoprotein B, and triglycerides in patients with primary hypercholesterolaemia, heterozygous and homozygous familial hypercholesterolaemia or combined (mixed) hyperlipidaemia when response to diet and other non ...
  
  
• Simvastatin (statin) - 50.64%
  As an adjunct to diet for reduction of total cholesterol, LDL-cholesterol, apolipoprotein B and triglycerides in primary hypercholesterolaemia, heterozygous familial hypercholesterolaemia or combined (mixed) hyperlipidaemia when response to diet and other non- pharmacological measures is inadequate ...
  
  
• LESCOL XL (statin) - 49.42%
  As an adjunct to diet for the reduction of elevated total cholesterol (total-C), low- density lipoprotein cholesterol (LDL-C), apolipoprotein B (apo B) and triglycerides (TG) levels and for the increase of high-density lipoprotein cholesterol (HDL-C) in patients with primary hypercholesterolaemia ...
  
  
• LIPOSTAT (statin) - 48.68%
  ... procedure in patients with a history of either a myocardial infarction or unstable angina pectoris and a total serum cholesterol level in excess of 4.8mmol/L or a LDL- cholesterol in excess of 3.2mmol/ L. Coronary atherosclerotic disease: adjunct to diet to slow progressve course of coronary ...
  
  
• CHOLESTAGEL Film-Coated Tablets - 47.95%
  ... reduction in LDL-cholesterol (LDL-C) levels in patients with primary hypercholesterolaemia who are not adequately controlled with a statin alone. Cholestagel as monotherapy is indicated as adjunctive therapy to diet for reduction of elevated total and LDL-cholesterol in patients with isolated ...